4D Molecular Therapeutics (NASDAQ:FDMT) said on Thursday that the U.S. FDA has granted the regenerative medicine advanced therapy (RMAT) status to 4D-150 as a treatment for diabetic macular edema.

The decision is backed by late-stage data showing visual acuity improvements.

Regenerative